Adjuvant therapy for soft tissue sarcomas.
Primary therapy for soft tissue sarcoma is predicated on surgical resection with an adequate margin of normal tissue. For high-risk patients, local control is improved with postoperative adjuvant radiation or intraoperative brachytherapy. Despite the most recent meta-analysis or encouraging phase II data for neoadjuvant chemotherapy, there is no clearly proven role for adjuvant or neoadjuvant chemotherapy in the treatment of sarcoma. Nevertheless, distinct subpopulations of sarcoma patients are appropriate for consideration of investigational neoadjuvant/adjuvant chemotherapy due to their high risk of distant metastasis and potential for chemoresponsiveness.
Lewis
J J
JJ
Department of Surgery, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York 10021, USA.
Benedetti
F
F
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D002648:Child; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007430:Intraoperative Care; D015201:Meta-Analysis as Topic; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011182:Postoperative Care; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012509:Sarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D015996:Survival Rate
D000970:Antineoplastic Agents